0.000USD0.000盘前交易 08/06, 09:30 (美东)
关键数据
1.100今开
1.110最高
15.41K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.04%换手率
1.060昨收
1.050最低
13.02K成交额
亏损市盈率静
4.81市净率
0.00%股息率 TTM
-38.95%ROA
3.13952周最高
-0.21量比
-6.18M净利润
38.57M总股本
-0.3597每股收益TTM
1.45Beta
-98.53%ROE
0.60552周最低
5.65%振幅
68.24%毛利率
43.29M总市值
-0.97回报/风险
5.52%风险率
操作建议
Myomo Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名81/200位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价4.42。中期看,股价处于上升通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Myomo Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Zimmer Biomet Holdings Inc
ZBH
29
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Myomo Inc简介
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
公司代码MYO
公司Myomo Inc
CEOGudonis (Paul R)
网址https://myomo.com/
公司股东
常见问题
Myomo Inc(MYO)的当前股价是 1.06。
现在Myomo Inc(MYO)的股票是买入、持有还是卖出?
根据分析师评级,Myomo Inc(MYO)的总体评级为买入,目标价格为4.42。
Myomo Inc(MYO)股票的每股收益(EPS TTM)是多少
Myomo Inc(MYO)股票的每股收益(EPS TTM)是-0.37。